A primary care-oriented summary of important 2023 medical studies, including retatrutide's phase 2 obesity trial. Highlights the landmark weight loss results as one of the key clinical findings of the year relevant to family physicians.
Thomas, Betsy S; Perry, Danielle; Moe, Samantha S; Turgeon, Ricky D; Potter, Jen; Braschi, Émélie; Dugré, Nicholas; Kirkwood, Jessica E M; Allan, G Michael